Clinical Trial: Siltuximab for the Prevention of CAR T Cell Related Cytokine Release Syndrome in Patients With CD19 Positive Non-Hodgkin Lymphoma
Study Status: Completed
Recruit Status: RECRUITING
Condition: Non-Hodgkin Lymphoma
Study Type: INTERVENTIONAL
Official Title: Phase I Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab
Brief Summary:
This phase I trial tests the safety and side effects of siltuximab in preventing CAR T cell therapy related cytokine release syndrome in patients with CD19 positive non-Hodgkin lymphoma.Several of the major complications of CD19 directed chimeric antigen receptor T-cell therapy (CD19.CAR-T) include cytokine release syndrome (CRS, a complication of a highly active immune system seen with some cancer treatments including CD19.CAR-T cell therapy) and immune effector cell therapy associated neurotoxicity (ICANS,…
Read more